ReviewJournal of current glaucoma practice
Pathogenesis of Uveitic Glaucoma.
Review in Journal of current glaucoma practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Pooled it
- In vivo analysis of Schlemm's canal axial dimensions in children with juvenile idiopathic arthritis-associated uveitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Quantitative Analysis of Background Intraocular Pressure Volatility and Retinal Nerve Fiber Layer Loss in Cytomegalovirus Anterior Uveitis.Translational vision science & technology · 2026Article
- Alopecia areata patients are associated with increased risk of glaucoma: a multicenter, retrospective cohort study.Frontiers in immunology · 2026Article
- Impact of complications in adult anterior uveitis in a Finnish single-centre registry study.BMJ open ophthalmology · 2025Article
- Factors associated with the avoidance of glaucoma surgery in secondary glaucoma due to ocular inflammatory disease.Journal of ophthalmic inflammation and infection · 2025Article
- Matrix molecules associated with both regulation of inflammation and pathogenic outcomes associated with the surface of the lens in the eyes of EAU mice.Experimental eye research · 2025Article
- Advances in the management of uveitic cataract: current strategies and emerging perspectives.International ophthalmology · 2025Review
- Article
- Ab externo open conjunctiva XENJournal of ophthalmic inflammation and infection · 2025Article
- The PAUL Glaucoma Implant in the management of uveitic glaucoma-3-year follow-up.Eye (London, England) · 2025Article
- The association between intraocular pressure dynamics during dark-room prone testing and intraocular pressure over a relatively long-term follow-up period in primary open-glaucoma patients.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Update on Diagnosis and Treatment of Uveitic Glaucoma.Journal of clinical medicine · 2024Review
- Treatment of uveitis and scleritis patients in Malaysia.International journal of ophthalmology · 2024Article
- Bifidobacterium promotes retinal ganglion cell survival by regulating the balance of retinal glial cells.CNS neuroscience & therapeutics · 2023Article
- Efficacy of ripasudil in reducing intraocular pressure and medication score for ocular hypertension with inflammation and corticosteroid.International journal of ophthalmology · 2023Article
- Updates on the Diagnosis and Management of Glaucoma.Mayo Clinic proceedings. Innovations, quality & outcomes · 2022Review
- Pathogenesis and Manifestations of Zika Virus-Associated Ocular Diseases.Tropical medicine and infectious disease · 2022Review
- Elevation of Tear MMP-9 Concentration as a Biomarker of Inflammation in Ocular Pathology by Antibody Microarray Immunodetection Assays.International journal of molecular sciences · 2022Article
- Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.Journal of inflammation research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveitic glaucoma consists one of the most serious complications of intraocular inflammation and, despite its rarity, is considered as one of the leading causes of preventable loss of vision worldwide. It has been associated with a wide spectrum of inflammatory diseases, but its pathogenesis is still not fully comprehended. It appears that the type of inflammation, the steroid-response and the anatomical alterations of the anterior chamber play a pivotal role. To our knowledge, the mechanisms may be both acute and chronic. The main targets of the treatment are to control the inflammation and reduce the intraocular pressure (IOP). The management of glaucoma associated with uveitis remains an extremely challenging condition for ophthalmologists. The successful treatment of uveitic glaucoma is inextricably correlated with prompt and immediate therapeutic decisions. Very often a solid collaboration between clinicians from different specialties may be required for treating the underlying disease. Further understanding of its pathogenesis can indicate therapeutic targets and may lead to the development of new and more efficient therapeutic approaches. New glaucoma surgical modalities may ameliorate the prognosis after surgical intervention, but this calls for further evaluation. This study aims to highlight the complexity of uveitic glaucoma analyzing the main pathogenetic mechanisms and the correlations with the inflammatory response. HOW TO CITE THIS ARTICLE: Kalogeropoulos D, Sung VCT. Pathogenesis of Uveitic Glaucoma. J Curr Glaucoma Pract 2018;12(3):125-138.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.